Research into a rare genetic condition called Laron syndrome is shedding new light on the global fight against cancer. The disorder, which affects only around 840 people worldwide, has been found to have a surprising protective effect against certain diseases. Scientists are now investigating how this natural resistance could be harnessed for broader therapeutic use.
Laron syndrome causes growth hormone insensitivity, resulting in short stature and significant challenges for those affected. However, researchers believe the unique biological profile of individuals with this condition may hold the key to understanding disease resistance. Dr Jaime Guevara, an endocrinologist who has studied Laron syndrome for 40 years, is leading efforts to discover how its effects could be replicated through medicine or diet in the wider population.
A major study spanning 22 years and involving over 100 individuals with Laron syndrome and 1,600 relatives of normal height in Ecuador found some remarkable results. The research team, which included Dr Valter Longo from the University of Southern California, reported no cases of diabetes among the Laron syndrome patients – a stark contrast to the 5% of the control group who developed the condition. Similarly, while 17% of the control group were diagnosed with cancer, there was only one non-fatal case in the Laron syndrome group.
Laron syndrome is relatively rare, affecting mainly people from the southern Ecuadorean provinces of El Oro and Loja. The condition was first identified by paediatrician Zvi Laron 60 years ago and affects individuals worldwide. Professor Laron, based at Tel Aviv University, is set to publish a new paper in July detailing all known cases between 1966 and 2025.
The research raises hopes that treatments could be developed to mimic the protective effects observed in Laron syndrome patients. If successful, this could open up entirely new avenues for preventing chronic diseases like cancer and diabetes, with significant implications for public health strategies globally – including in the UK.